Group One Trading’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-24,190
| Closed | -$583K | – | 8486 |
|
|
2023
Q1 | $583K | Sell |
24,190
-164,152
| -87% | -$2.06M | ﹤0.01% | 2625 |
|
|
2022
Q4 | $1.99M | Buy |
188,342
+43,659
| +30% | +$352K | ﹤0.01% | 1820 |
|
|
2022
Q3 | $651K | Buy |
144,683
+70,102
| +94% | +$319K | ﹤0.01% | 2966 |
|
|
2022
Q2 | $298K | Buy |
+74,581
| New | +$354K | ﹤0.01% | 3914 |
|
|
2022
Q1 | – | Sell |
-65,482
| Closed | -$392K | – | 9014 |
|
|
2021
Q4 | $368K | Sell |
65,482
-18,215
| -22% | -$116K | ﹤0.01% | 4463 |
|
|
2021
Q3 | $536K | Sell |
83,697
-74,556
| -47% | -$479K | ﹤0.01% | 4123 |
|
|
2021
Q2 | $1.33M | Buy |
+158,253
| New | +$1.28M | ﹤0.01% | 3083 |
|
|
2021
Q1 | – | Sell |
-53,742
| Closed | -$756K | – | 8187 |
|
|
2020
Q4 | $910K | Sell |
53,742
-16,533
| -24% | -$248K | ﹤0.01% | 2729 |
|
|
2020
Q3 | $902K | Buy |
70,275
+1,199
| +2% | +$15.1K | ﹤0.01% | 2293 |
|
|
2020
Q2 | $975K | Buy |
69,076
+24,950
| +57% | +$315K | ﹤0.01% | 2041 |
|
|
2020
Q1 | $406K | Buy |
44,126
+37,192
| +536% | +$479K | ﹤0.01% | 2207 |
|
|
2019
Q4 | $103K | Buy |
6,934
+3,008
| +77% | +$26.8K | ﹤0.01% | 3621 |
|
|
2019
Q3 | $27K | Buy |
+3,926
| New | +$39.7K | ﹤0.01% | 4253 |
|
Other funds holding PRVB
Group One Trading's PRVB Position: Q2 2023 in Review
Group One Trading sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 24,190 shares — an estimated $583K sold.
Group One Trading first reported a position in PRVB in Q3 2019 and held it in 13 quarters. The position peaked at $1.99M in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Group One Trading reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Group One Trading sold 24,190 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $583K.
- Group One Trading first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 13 quarters.
- Group One Trading's Provention Bio, Inc. Common Stock position peaked at $1.99M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.